Exploration of new azole derivatives containing ethanolamine moiety as anti-UC agents by inhibiting NF-κB/MAPK pathways.

Ulcerative Colitis (UC) is a recurrent inflammatory bowel disease with a long and difficult treatment cycle. In this work, a series of new azole derivatives containing ethanolamine moiety have been prepared, and their anti-inflammatory activities were tested. The results indicated that ethanolamine moiety was beneficial for increasing the anti-inflammatory activity of azole derivatives, and most of them showed good inhibition of NO generation. In vivo experiments have shown that 7f could reduce the levels of TNF-α and IL-1β cytokines, significantly inhibit the phosphorylation level of p65 NF-κB, and down-regulate the phosphorylation of ERK and JNK on DSS-induced UC model. Therefore, these azole derivatives may be considered as new anti-UC agents by inhibiting NF-κB/MAPK signaling pathways.